STAT+: At ASCO, AstraZeneca says its CAR-T therapy shrank solid liver tumors in early trial

STAT June 3, 2024
Angus Chen

CHICAGO — A next-generation CAR-T therapy was able to substantially shrink tumors in patients with liver cancer in early clinical data presented Monday at the American Society of Clinical Oncology annual meeting. The study, though preliminary and small with only 24 patients, represents a triad of firsts for one of the trial’s sponsors.

“It’s the first CAR therapy working in liver cancer. First validation of targeting GPC3 as a target. It’s the first validation of our armoring strategy. And it’s the first...

Today's Sponsors

Today's Sponsor